Jump to navigation
Chiasma is a biopharmaceutical company focused on evolving orphan medications to better meet the needs of patients and healthcare professionals. Our first priority is the development and commercialization of octreotide capsules – the only oral somatostatin analog. This means the chance to avoid painful needles and minimize symptoms that can arise as traditional injections wear off. It’s a new way of addressing treatment that’s providing a real sense of hope.
What if you could maintain control of a disease with capsules instead of injections? That’s exactly what a multicenter, Phase 3 study demonstrated with octreotide capsules in people living with acromegaly – a rare endocrine disease affecting the whole body. The results have been published in the Journal of Clinical Endocrinology and Metabolism and Chiasma is currently seeking FDA approval for this first-in-class oral treatment.
Chiasma is driven by the need to improve peoples’ lives. We do this through a proprietary technology platform. We do it by developing and commercializing novel oral medications that were previously available only by injection. And we do this through collaboration with healthcare professionals and the patient community. For people who have been struggling with painful and burdensome injections – often for years – the result can be truly transformational.